It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract

Background

 Brugada syndrome (BrS) is an arrhythmic disorder associated with an increased risk of sudden cardiac death; however, current treatment options are limited due to their side effects and variable efficacy. **Methods** In this study, we first employed Mendelian randomization analysis utilizing proteomic, transcriptomic, and metabolomic data to identify potential therapeutic targets for BrS. Ex vivo perfused heart models were used to assess the effects of the potential targets on action potentials and QT intervals. Calcium indicators were employed to evaluate calcium homeostasis in primary

cardiomyocytes, and patch-clamp techniques were used to investigate the impact on Nav1.5 and

TRPC5 channels.

Results

 Our findings indicate that N-palmitoyl glycine (PalGly) is linked to an increased risk of BrS and interacts with BrS-associated proteins, demonstrating moderate binding affinities for DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA. Electrophysiological experiments showed that although PalGly does not interact with Nav1.5, it enhances calcium sparks in ventricular cardiomyocytes. We determined that the calcium-modulating effect of PalGly is mediated by its binding to and activation of the transient receptor potential channel 5 (TRPC5) channel. Furthermore, PalGly was found to shorten the QT interval and action potential duration in Langendorff-perfused rabbit hearts and isolated rabbit cardiomyocytes. Transcriptomic and lipidomic analyses of PalGly-treated neonatal rat cardiomyocytes revealed significant negative

modulation of immune pathways, akin to the effects observed with agonizing TRPC5.

Conclusion

- Our study underscores the involvement of PalGly, TRPC5, and inflammation-related proteins in
- the pathophysiology of BrS.

Introduction

Methods

BrS cohort and ECG-wide association study

 Summary-level statistics for BrS were obtained from a meta-analysis study comprising 2,820 64 unrelated cases and 10,001 controls of European ancestry⁴. The diagnosis followed the guidelines from the 2013 Heart Rhythm Society, European Heart Rhythm Association and Asia Pacific Heart 66 Rhythm Society expert consensus statement⁵, the 2015 European Society of Cardiology 67 guidelines⁶ and the 2017 American Heart Association guidelines⁷. Inclusion criteria required a type

 1 BrS ECG, characterized by coved-type ST elevation at baseline (spontaneous) or after a drug challenge test, in one or more leads of the right precordial leads (V1 and/or V2), either in the standard (fourth intercostal space) or higher positions (second or third intercostal spaces). Diagnostic ECGs were centrally reviewed by a cardiac electrophysiologist experienced in BrS to confirm that the diagnostic criteria were met. The genetic associations were adjusted for the first six genetic principal components, SNPs that were missing in four or more of the ten strata, as well 74 as those with a heterogeneity test $P < 1e-6$ were excluded. Top variants of significant exposures 75 were looked up in ECGenetics (http://www.ecgenetics.org)⁸ to explore their effect on R-R adjusted three-lead exercise electrocardiogram (ECG) morphology. The GWAS for ECG morphology consists of comprehensive deep phenotyping of 77,190 ECGs in the UK Biobank across the complete cycle of cardiac conduction, resulting in 500 spatial-temporal data points. 79 Summary-level statistics for QTc consists of 84 630 UK Biobank pariticipants⁹.

⁸⁰ **Multi-omics GWAS data source**

81 Summary-level statistics of genome-wide association studies (GWAS) for two protein quantitative 82 trait loci (pQTL) studies were obtained from deCode genetics¹⁰ and UKB-PPP¹¹. Proteomics from 83 deCode genetics consists of 4,907 circulating proteins in 35,559 Icelanders measured by 84 SOMAscan version 4. Proteomics from UKB-PPP consists of 2,923 circulating proteins measured 85 by Olink technology in 54,219 UK Biobank participants with the most European ancestry (around 86 95%). The protein level of these two studies was inverse rank normalized to perform 87 covariates-adjusted genetic association. In addition, eQTL data was obtained from the eQTLgen 88 Consortium which measured transcriptomics by arrays and RNA-seq from 311,684 blood and

89 PBMC (peripheral blood mononuclear cell) samples (Predominantly European ancestry)¹². 90 Summary-level statistics of genetic associations with inverse rank normalized levels of 1,091 91 blood metabolites and 309 metabolite ratios quantified by the Metabolon HD4 platform in 8,299 92 unrelated European ancestry individuals from the Canadian Longitudinal Study on Aging (CLSA) 93 cohort¹³ were obtained.

⁹⁴ **Cardiometabolic traits**

95 A total of 28 cardiometabolic traits were included, including lipids (total cholesterol, triglycerides, 96 high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), 97 apolipoprotein A1 and B (ApoA1, ApoB), and lipoprotein A $Lp(a)$ ^{14,15}, blood pressure (systolic 98 blood pressure (SBP), and diastolic blood pressure (DBP) ¹⁶, glycemic traits (fasting glucose, 99 fasting insulin, 2-hour post-challenge glucose, and $HbA1c$ ^{17,18}, and anthropometric traits (body 100 mass index (BMI), waist circumference, hip circumference, and waist-to-hip ratio)¹⁹. With 11 101 cardiometabolic diseases, including atrial fibrillation (AF), stroke and stroke subtypes (large artery 102 atherosclerosis, small-vessel, and cardioembolic)²⁰, coronary heart disease (CHD)²¹, heart failure 103 $(HF)^{22}$, aortic aneurysms²³, chronic kidney disease²⁴, type 1 diabetes²⁵ and type 2 diabetes²⁶. Most 104 participants in these cohorts were of European ancestry (Table S1).

¹⁰⁵ **Exposure instrument variables selection**

106 Genome-wide suggestive SNPs ($p < 1e-6$) in weak linkage disequilibrium ($r^2 < 0.1$, based on the 107 1000 Genomes Phase 3 European reference panel) within \pm 1 Mb from target gene loci associated 108 with the proteins were obtained. Independent effect SNPs for metabolites QTL were identified by 109 genome-wide suggestive threshold ($p < 1e-6$) and were clumped by a 1Mb distance with a linkage

110 disequilibrium threshold $r^2 = 0.1$. Clumping was performed by Plink version 1.9²⁷. F-statistics of 111 less than ten were used to exclude SNPs that were weak instruments for a limited proportion of the 112 variance explained.

¹¹³ **MR analysis**

 The included cohorts consist of almost European ancestry, no individuals likely to overlap. Two-sample MR analysis based on indexed SNPs for circulating proteins, RNAs, and metabolites was used to capture the associations with the risk of BrS. An inverse variance weighted (IVW) random-effects model was employed to estimate the causal effects of genetically proxied targets on BrS. Bonferroni correction was used to account for multiple tests. Weighted median, MR Egger and Steiger test were used to employ sensitivity analysis, heterogeneity test, and causal direction 120 test. All MR analyses were performed in R version 4.3.2 by TwoSampleMR package²⁸. Findings were reported according to the STROBE-MR (Strengthening the Reporting of Mendelian 122 . Randomization Studies) guidelines²⁹.

¹²³ **Colocalization analysis**

124 Colocalization analysis was employed by the coloc R package³⁰ to test whether identified 125 exposures and BrS were associated and shared the same causal variant within ± 1 Mb from target 126 gene loci associated with the proteins. We set prior probabilities of the SNP being only associated 127 with exposure (p1) or outcome (p2) at 1e-4; and the probability of the SNP being associated with 128 both traits (p12) at 1e-5, posterior probability for shared causal variants (PPH4) \geq 0.8 were 129 considered to have strong evidence of colocalization. The set of significant genes and proteins 130 with high colocalization support was set forth to an overrepresentation analysis using the

- pathways described in the Gene Ontology and the KEGG database. Selected pathways were those
- 132 significantly enriched at an FDR <0.05.

Mediation analysis

 We explored the mediation effect of circulating proteins on BrS via metabolites using the delta 135 method to approximate confidence intervals by the RMediation package³¹. The MR estimate for the mediated effect of genetically predicted levels of circulating metabolites on BrS was divided by the total effect of genetically predicted levels of circulating proteins on BrS risk estimated in the IVW univariable MR, with standard errors estimated using the propagation of error method to calculate mediation proportion.

Molecular Docking

- The 3D structures of DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA
- were obtained from RCSB Protein Data Bank (PDB ID: 2ED7, 2ED8, 2ED9, 2EDB, 2EDD,
- 2EDE, 2MCY, 2MCZ, 3AI8, 1HUC, 6DXW, 6DXX, 1IJV, 2K1K, 2K1L, 7WRQ, 4MXV, 4MXW)
- and was subjected to processing through the pdb2pqr before initiating the docking analysis. The
- 145 entire docking process was conducted using Autodock vina 1.2.0 by Dockey graphical interface³²
- with default parameters. The visualization was performed by PyMOL 3.0.3.

Isolation of rabbit cardiomyocytes

148 Rabbit ventricular cardiomyocytes were isolated enzymatically, as previously described³³. The 149 animal used in this study conformed to the "Guide for the Care and Use of Laboratory Animals" published by the US National Institutes of Health (NIH Publication No. 85-23, revised 2011). The

 ethical clearance was granted by the Institutional Animal Care and Use Committee of Peking University First Hospital (approved number: J2024090), affirming the conscientiousness of their treatment and welfare. Male New Zealand rabbits weighing 2.5 to 3.0 kg (approximately 3-month-old, Fangyuanyuan, China) were anaesthetized with xylazine (16 mg/kg, Huamu; China) and ketamine (40 mg/kg CAHG; China) (IV) and injected with 5,000 units/kg of heparin. The absence of pain response and corneal reflex served as the indicators to ascertain the appropriate level of anaesthesia depth. Rabbit hearts were rapidly excised and retrogradely perfused through the aorta on a standard Langendorff apparatus for 10 min at a flow rate of 10 mL/min with a 159 calcium-free Tyrode solution continuously gassed with 100% O_2 at 37 °C. The hearts were perfused in a recirculating manner for 40–60 min (ventricular cardiomyocytes) with 100 mL of calcium-free Tyrode solution containing 60 mg of collagenase (type II, Sigma) and 100 mg of bovine serum albumin (BSA, Sigma). The enzymes were washed out for 5 min via perfusion with a calcium-free Tyrode solution. The ventricles were cut into small chunks, and the tissue was manually pipetted with a disposable plastic transfer pipette for 1-2 min to mechanically separate the cells. The cell and enzyme mixture were filtered through a 200-micron nylon mesh into centrifuge tubes and the cells were stored in KB solution. Cells of approximately the same length and with clear stripes, a rod shape, a clean and smooth surface, and no spontaneous contractions over 1 minute of observation were selected for use in the experiments. The animal use was approved by the Institutional Animal Care and Use Committee of Peking University First Hospital. The isolated cardiomyocytes were then incubated with N-palmitoyl glycine (MedChemExpress) for at least 15 min to study its effect on action potential and calcium spark.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Isolated Rabbit Heart Assay

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.10.21.24315897;](https://doi.org/10.1101/2024.10.21.24315897) this version posted October 22, 2024. The copyright holder for this

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Whole-Cell Voltage-Clamp Recordings of NaV1.5 Channels in HEK293T Cells

194 The HEK293T cells were grown in culture dishes for 24 h, and plasmids expressing $\text{Nav}1.5$ (NM_198056) were transfected into HEK293T (National Collection of Authenticated Cell Cultures, China) cells using lipofectamine 3000 (Thermo Fisher Scientific). The extracellular 197 Solution (mM) contained: 137 NaCl, 1 MgCl₂·6H₂O, 4 KCl, 1.8 CaCl₂·2H₂O, 10 D-Glucose, 10 mM HEPES, adjusted to pH 7.4 with NaOH. The intracellular Solution (mM) contained: 50 CsCl, 60 CsF, 10 HEPES, 20 EGTA, and 10 NaCl, adjusted to pH 7.2 with CsOH. Patchmaster software, coupled with an EPC-10 amplifier (EPC-10, Heka Electronic, Germany), was used to collect and 201 store electrophysiological data. Electrodes (1-3 M Ω) were pulled from 1.5-mm borosilicate glass filaments using a P1000 micropipette puller. The holding potential was set at -120 mV, with a series of square-wave pulses from -120 to -10 mV in 10 mV increments for 8000 ms, followed by 204 a step to -10 mV for 30 ms, and then returning to -120 mV. The data were fitted to the Boltzmann equation to derive the steady-state inactivation curve. The holding potential was set at -120 mV, followed by depolarization to 0 mV for 20 ms to stimulate the resting-state sodium channel current. The voltage was then stepped to the condition pulse voltage corresponding to the 208 half-inactivation voltage ($V_1/2$) for 8000 ms, followed by repolarization to -120 mV for 30 ms. Subsequently, depolarization to 0 mV for 20 ms stimulated the half-inactivated state sodium channel current. Finally, the potential was returned to -120 mV, with current recordings taken every 20 seconds. Once steady-state current values were achieved, cumulative drug application 212 was performed, starting with negative control $(0.1\%$ DMSO) followed by 1 μ M PalGly.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.10.21.24315897;](https://doi.org/10.1101/2024.10.21.24315897) this version posted October 22, 2024. The copyright holder for this

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

²¹³ **Whole-Cell Voltage-Clamp Recordings of TRPC5 Channels** ²¹⁴ **in HEK293 Cells**

215 The HEK293T cells (China Infrastructure of Cell Line Resource) were grown in culture dishes for 216 24 h, and plasmids expressing hTRPC5 (NM_012471) were transfected into HEK293T cells using 217 lipofectamine 3000. The extracellular Solution (mM) contained: 145 NaCl, 4 KCl, 1 MgCl₂·6H₂O, 218 2 CaCl2·2H₂O, 10 D-Glucose, 10 HEPES, adjusted to pH 7.4 with NaOH. The intracellular 219 Solution (mM) contained: 120 Cs-aspartic acid, 20 CsCl, 2 MgCl2·6H₂O, 8.8 CaCl₂·2H₂O, 10 220 EGTA, 10 HEPES, 2 Na₂-ATP, adjusted to pH 7.2 with CsOH. Once a whole-cell seal is 221 established, the cell membrane potential is clamped at -80 mV. The voltage is stepped from 0 mV 222 to -100 mV and maintained for 1 ms, followed by a ramp to 100 mV for 300 ms, and then 223 repolarized to 0 mV for 50 ms. Data collection is repeated every 10 seconds to observe the effects 224 of the PalGly on the TRPC5 current.

²²⁵ **Whole-cell current recording for ventricular cardiomyocytes**

226 The extracellular Solution (mM) contained: 137 NaCl, 4 KCl, 10 HEPES, 10 D-Glucose, 1 227 MgCl₂·6H₂O, 2 CaCl₂·2H₂O, adjusted to pH 7.4 with NaOH. The intracellular Solution (mM) 228 contained: 135 KCl, 2 MgCl₂·6H₂O, 10 HEPES, 1 EGTA, 4 Mg-ATP, 0.3 NaGTP, adjusted to pH 229 7.2 with KOH. All the experiments were performed at a temperature of 23 ± 1 °C. For ventricular 230 cardiomyocytes, the cells are clamped at -80 mV, and the recording is switched to the current 231 clamp mode with $I = 0$. Ventricular myocytes require stimulation to generate action potentials. The 232 parameters for the inward current pulse stimulation are as follows: duration of 10 ms and 233 stimulation amplitude ranging from 0.1 to 1 nA.

234 **Measurements of Ca²⁺ sparks**

 Isolated cardiomyocytes were subjected to a fluorescent calcium indicator, Fluo-4-AM (Invitrogen), for 15 minutes at room temperature. Following this incubation period, the cells 237 underwent centrifugation, after which the supernatant was carefully removed. The cells were then resuspended in fresh Tyrode solution containing 250 μmol/L probenecid sodium for an additional 20 minutes to facilitate the de-esterification of the dye and was carried out in laminin-coated dishes. Cytosolic Ca2+ levels were monitored utilizing a confocal microscope (Leica SP8; Leica, 241 Wetzlar, Germany) operating in line-scan mode at a frequency of 700 Hz. Ca^{2+} sparks were invoked after a 20-second field stimulation (1Hz, 4ms, 40V) with a stimulator (MyoPacer EP, IONOPTIX). The subsequent detection and quantification of calcium sparks were performed by 244 SparkMaster 2^{34} .

Lipidomic and transcriptomic analysis

 To extract cardiomyocytes, using ice-cold ethanol to anesthetize neonatal rats (0-3 days) followed by cervical dislocation for euthanasia. Dissect immediately the chest cavity to remove the heart. Place the heart in a petri dish containing cold PBS buffer. Cut the heart into small pieces and isolate cardiomyocytes using a neonatal Cardiomyocyte Isolation Kit, rat (Miltenyi Biotec, Germany) according to its protocol. After 1 hour of differential adherence, the suspending cells were considered cardiomyocytes and were transferred to culture flasks containing DMEM supplemented with 20% FBS for continued culture over 48 hours. Following this, the medium is replaced with serum-free DMEM for 24 hours, after which 1 μM PalGly (dissolved in DMSO) or an equivalent volume of DMSO is added for an additional 24-hour incubation. Subsequently, the

Statistical analysis

- Data from the same cells or hearts before and after treatment are analyzed using a paired samples
- t-test, while comparisons between different cell groups are conducted using an two-sided
- independent samples t-test. The concentration-response curves were fitted to a four-parameter Hill
- equation. All analyses were performed in R 4.3.2 and GraphPad Prism 10.2.3.

Ethics

- The UKB participants gave informed written consent, and ethical approval was obtained from the
- North West Centre for Research Ethics Committee. The deCode participants who donated samples
- gave informed consent, and the National Bioethics Committee of Iceland approved the study. The
- All GWAS human participants provided written informed consent, and all studies had received
- approval from the appropriate ethical review boards.

Results

The flowchart of the MR design is presented in **Figure 1**. Instrument variables used in this study

are presented in **Table S2-5**.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.10.21.24315897;](https://doi.org/10.1101/2024.10.21.24315897) this version posted October 22, 2024. The copyright holder for this

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Circulating transcripts and proteins that causally associated with the risk of BrS

The overview of the results of MR and colocalization analysis is presented in **Figure 2**. A total of

- nine proteins (H6PD, ANXA4, CXCL6, LRP11, CTSB, DEFB1, PDGFD, SPATA20, GSS) from
- 277 deCode genetics reached the Bonferroni corrected threshold ($p < 0.05/1320$) among which four
- 278 proteins (CXCL6, CTSB, SPATA20, DEFB1) were with high colocalization support (PPH₄ > 0.8)
- (**Table 1**), while 13 proteins (CR1, CXCL6, NAAA, ARSB, HCG22, LTA, CTSB, IGFBP3,
- EPHA1, ECHDC3, AAMDC, ZFYVE19, DCC) from UKB-PPP reached Bonferroni corrected
- threshold (p < 0.05/ 1590) among which eight proteins (CR1, CXCL6, NAAA, LTA, IGFBP3,

EPHA1, AAMDC, DCC) were with high colocalization support. In addition, 12 genes at the

- transcript level with high colocalization support from eQTLgen were significantly associated with
- BrS (LUZP1, PCYOX1, NEIL2, MFHAS1, FAM86B3P, SCAND2P, C15orf26, ZSCAN2,
- ADAMTS17, UBTF, DESI1, EP300). Detailed results are presented in **Table S6-9**. Enrichment
- analysis showed that IGFBP3 and EPHA1 were significantly associated with fibronectin-binding
- (GO:0001968) after FDR adjustments.

3.2 Circulating protein levels affect genetically proxied ECG morphology

 Despite the main ECG characteristics of BrS present in the right precordial leads, causal inference of circulating proteins on three-lead exercise ECG morphology GWAS may unveil potential mechanisms. For proteins that passed both MR and colocalization thresholds, top cis-pQTLs were selected to represent the expression of the specific proteins (Figure S1). The AAMDC, CXCL6,

3.3 IGFBP3 increases the risk of BrS and is mediated by N-palmitoyl glycine

 A total of 69 circulating metabolites were nominally significant, and only one metabolite (N-palmitoyl glycine, PalGly) reached the Bonferroni corrected threshold (p < 0.05/1190) (**Table S9**). Genetically proxied circulating PalGly significantly increased the risk of BrS (per SD, OR 1.42, 95% CI 1.20-1.67). Mediation analysis showed that one causally BrS-associated circulating protein (IGFBP3) increased the risk of BrS partly via PalGly (Table 2).

3.4 PalGly, IGFBP3, CR1, and DCC reduce the risks of cardiometabolic diseases while CXCL6 increases the risks

 To determine potential therapeutic targets for BrS, we performed MR analyses of the genetically proxied PalGly and proteins on 28 cardiometabolic traits. Surprisingly, PalGly reduced the risks of AF and HF, which was in discordance with its effect on BrS (Table 3). The IGFBP3 showed similar effects with the PalGly with reduced cardiometabolic ischemic stroke risk (Table 4). The CXCL6 increased the risk of AF while CR1 and DCC reduced the risk of cardioembolic strokes

 and HF respectively. The effects of the CXCL6, CR1, and DCC toward the cardiometabolic traits were in concordance with their effects towards BrS, indicating these targets were therapeutic. Detailed results of potential targets on cardiometabolic traits were presented in **Table S10**.

3.5 PalGly may directly bind to BrS-associated proteins

 We performed molecular docking of the PalGly with target proteins. The max binding affinities obtained were -5.4 kcal/mol for DCC, -5.8 kcal/mol for CR1, -5.9 kcal/mol for CTSB, -7.6 kcal/mol for NAAA, -5.8 kcal/mol for EPHA1, -5.7 kcal/mol for IGF1/IGFBP3/ALS complex, and -6.3 kcal/mol for LTA, indicating that the PalGly has the moderate predicted interaction with these targets (**Table S11**). Docking results also revealed that the PalGly forms three hydrogen bonds and exabits three hydrophobic interactions with DCC, forms three hydrogen bonds and exabits four hydrophobic interactions with CR1, forms two hydrogen bonds and exabits seven hydrophobic interactions with EPHA1, and forms one hydrogen bond and exabits five hydrophobic interactions with IGF1/IGFBP3/ALS complex, suggests stable binding conformations.

3.6 PalGly does not interact with Nav1.5 but increases calcium sparks of ventricular cardiomyocytes

 Mutations in the SCN5A gene are the most known in BrS, therefore we first investigated whether 332 PalGly administration under maximum solubility (1 μ M) can affect peak sodium current (Na_v1.5), and results showed that the effect was not significant (**Figure 3A**). Next, because the PalGly can 334 induce calcium influx in neurons³⁵, we investigate its effect on calcium spark on rabbit primary ventricular cardiomyocytes. After 1 μM PalGly infusion and at least 20-second 1 Hz field

 stimulations, the amplitude of calcium sparks was significantly increased (**Figure 3B**) with increased width, duration, and frequency, while the time to peak of sparks was significantly reduced.

3.7 PalGly activates the hTRPC5 channel

 $P_1 = P_2$ PalGly activates a TRP-like channel in dorsal root ganglia³⁵, and there is speculation that PalGly is 341 a direct transient receptor potential (TRP) channel 5 (TRPC5) agonist³⁶. Therefore, we performed molecular docking that showed PalGly can bind both class 1 & 2 hTRPC5 channels. The docking results for class 1 hTRPC5 (the dominant one) were presented in **Figure 4A,** the binding affinity for class 2 hTRPC5 was -5.9 kcal/mol, and PalGly forms two hydrogen bonds in Chain A (Gln507, Trp435) and exhibits five hydrophobic interactions (Chain A: Ile484, Leu491, Leu514; Chain D Thr603, Thr607). Next, we expressed hTRPC5 in HEK293 cells to perform whole-cell patch-clamp recording. The results demonstrated that PalGly significantly increased 348 both inward and outward currents of hTRPC5 at its maximum solubility (1µM), with the outward current increasing by approximately two-fold and the inward current increasing by approximately six-fold, and these currents can be diminished by the TRPC5 inhibitor ML204 (**Figure 4B**). Since 351 1 µM reached the maximum solubility of PalGly, it was not possible to calculate the EC50 value for PalGly activating hTRPC5. Consequently, we calculated the EC50 value for PalGly to be approximately 104 nM (inward current) and 128.3 nM (outward current) by co-administering 20 µM of the TRPC5 selective agonist rosiglitazone (**Figure 4C**).

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.10.21.24315897;](https://doi.org/10.1101/2024.10.21.24315897) this version posted October 22, 2024. The copyright holder for this

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

3.8 PalGly shortens action potential duration and QT interval

 We subsequently investigated the effects of PalGly on isolated primary rabbit ventricular myocytes and Langendorff-perfused hearts. After administering or perfusing 1 μM PalGly for at least 10 minutes, we observed a significant shortening in the action potential duration (APD) of both cardiomyocytes (**Figure 5A**) and the overall heart, as well as a significant shortening of the QT interval (**Figure 5B**). Notably, the influence of PalGly appeared to be more pronounced on early repolarization, as indicated by a greater difference in APD30/MAPD30 compared to APD90/MAPD90. Given that rosiglitazone can suppress several cardiac transmembrane ion 364 currents³⁷, we did not use it as a TRPC5 positive control. We further assessed the impact of PalGly on QTc through MR analysis, confirming a causal relationship between PalGly and a shortened 366 OTc interval (per SD, β -0.54, 95% CI -1.01, -0.07, p = 0.03).

3.9 PalGly alters the transcriptomic and lipidomic profile of cardiomyocytes

 We added a concentration of 3000 ng/ml of PalGly to the culture medium of primary neonatal rat cardiomyocytes for 24 hours. Mass spectrometry quantification of the culture medium revealed 371 that the PalGly concentration decreased to 20.18 ± 16.68 ng/ml, while in the medium of normally 372 cultured cardiomyocytes, the PalGly concentration was approximately 0.24 ± 0.16 ng/ml. Next, following administration with 1 μM PalGly for 24 hours, we extracted the culture medium to perform non-targeted lipidomic analysis, and RNA for RNA-seq and subsequent transcriptomic analysis. Five lipid species were significantly reduced (LPC 18:1, PA 33:1; PA 16:0-17:1, CL 68:3;

4.0 Discussion

 Through conducting MR and colocalization analysis involving over 4000 proteins and 1000 metabolites, we have identified several previously unreported potential BrS targets as well as discovered the similarities and differences of these targets' effects on BrS and other cardiometabolic disorders. Our MR analysis and colocalization analysis using eQTLs showed minimal overlap compared to the results by pQTLs. Given that proteins are regarded as primary function executors, we focused on investigating the proteome/metabolome-wide results. Combining the MR and colocalization results, we found that genetically predicted CXCL6 increased the risks of BrS and AF, and CR1 and DCC reduced the risks of BrS, leading to lower risks of cardioembolic stroke and HF respectively. PalGly and IGFBP3, on the other hand,

 increased the risk of BrS while reducing the risks of cardiometabolic diseases. Interestingly, molecular docking analysis revealed that PalGly not only has the potential to influence BrS risk itself but can also interact with BrS-related proteins (DCC, CR1, CTSB, NAAA, DEFB1, EPHA1, IGF1/IGFBP3/ALS, and LTA). Although mediation analysis indicated that only IGFBP3 exhibited a significant mediating effect. Furthermore, we identified for the first time that PalGly can enhance myocardial calcium sparks and shorten action potential duration (APD) and QT interval, with these electrophysiological effects likely mediated by the activation of TRPC5. Although traditionally considered as a pure electrical disorder without structural alteration, there is accumulating evidence suggesting that myocarditis and inflammation infiltration may 406 contribute to BrS pathogenesis , and C-reactive protein (CRP) was found to be an independent 407 marker for symptomatic $BrS³⁹$. Myocardial inflammation was detected in two patients with BrS 408 and arrhythmic storm by fluorodeoxyglucose–positron-emission tomography (FDG-PET)⁴⁰. One patient remained free of ICD shocks for 1 year after immunosuppression therapy. However, these studies were either cases or cross-sectional investigations, lacking robust and causal evidence. The CXCL6, CR1, and DCC screened by our analyses are proteins associated with immune response. 412 CXCL6 primarily exerts pro-inflammatory effects by recruiting neutrophils⁴¹ and acts as a pro-angiogenic and pro-fibrotic paracrine factor secreted by endothelial cells and cardiac 414 progenitor-like cells^{41,42}. Elevated levels of CXCL6 are associated with higher idiopathic 415 pulmonary fibrosis mortality⁴³. CR1, on the other hand, exerts anti-inflammatory effects by 416 facilitating the clearance of immune complexes and inhibits both C3 and C5 convertase activity⁴⁴. Interestingly, administration of a recombinant form of soluble CR1 (TP10/CDX-1135) led to a decreased incidence of cardiovascular events in specifically male individuals undergoing cardiac

419 surgery on cardiopulmonary bypass⁴⁵. Gender difference is a well-recognized pattern of BrS, 420 female patients with BrS are much rarer⁴⁶, and the cohort included in this study is predominantly comprised of male participants (74%), suggesting inflammation may contribute to the gender difference of BrS. DCC is a netrin-1 receptor that is also involved in inflammation and 423 angiogenesis and exerts its cardioprotective effect via Nitric oxide (NO) sustaining⁴⁷. In-vitro evidence suggests that the cardioprotective effects exerted by netrin-1 in ischemia-reperfusion injury are by DCC-dependent endothelial-derived and cardiomyocyte-derived NO. Taken together, the immune/inflammation response is likely involved in the pathogenesis of BrS, and pharmacotherapies targeting these targets may hold promise as potential interventions.

 Lipidomic and transcriptomic analyses indicated that PalGly negatively regulates the innate immune response, a finding that parallels the effects of TRPC5. PalGly is one of the fatty acid 430 amides that serves as an endogenous signalling molecule⁴⁸. It presents around 250-fold greater 431 amounts in the skin (1612 pmol/g) compared to the amounts in the heart (6 pmol/g)³⁵. Under the concentration of 27 μM, it potently inhibits heat-evoked firing of nociceptive neurons in rat dorsal horn and induced transient calcium influx in adult rat dorsal root ganglion (DRG) cells and a 434 DRG-like cell line $(F-11)^{35}$. Our results demonstrate that PalGly significantly increased the calcium spark amplitude in adult rabbit ventricular cardiomyocytes under field stimulation. Additionally, it augmented the width, duration, and frequency of calcium sparks while decreasing the time to peak. PalGly also significantly shortened APD both in vivo and ex vivo and shortened QT interval. We identified PalGly as an endogenous TRPC5 activator through patch-clamp experiments, the agonizing effect can be abolished by the TRPC5 inhibitor ML204. TRPCs 440 contribute to Ca^{2+} signalling and changes in cell excitability. TRPC5 channels, like PalGly, are

 In addition, It was reported that IGFBP3 is significantly associated with higher sudden 457 cardiac arrest (SCA) and syncope in the SCN5A mutation− BrS patients⁵⁴ and higher serum 458 calcium⁵⁵. Our results showed that genetically predicted circulating IGFBP3 is associated with a higher risk of BrS, and the effect is partly mediated by the PalGly.

 As BrS is relatively rare, we were unable to replicate our current findings through other cohorts. The cohorts available to us consisted of individuals of European ancestry, which may limit the generalizability of our results, particularly considering the higher prevalence of BrS in

- 463 Southeast Asia⁵⁶. We also were unable to perform sex-stratified and mutation-stratified analyses
- due to a lack of available summary-level statistics.
- Collectively, our study underscores the involvement of PalGly, TRPC5, and
- inflammation-related proteins in the pathophysiology of BrS.

Funding

 This work was funded by the Chinese National Natural Science Foundation (Grant No. 81930105 and 82370312).

Acknowledgements

 L.W. is supported by the National Natural Science Foundation of China (No. 82370312 and 81930105). This work was supported by High-performance Computing Platform of Peking University. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The authors thank members of all contributing studies 475 for sharing their summary-level GWAS data.

Conflict of interests

None declared.

Reference

 1 Brugada, P. & Brugada, J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic 481 syndrome. A multicenter report. J Am Coll Cardiol 20, 1391-1396 (1992).

https://doi.org/10.1016/0735-1097(92)90253-j

- 483 2 Monasky, M. M. et al. Genotype-Phenotype Correlation in a Family with Brugada
- 484 Syndrome Harboring the Novel p.Gln371* Nonsense Variant in the SCN5A Gene. Int J
- Mol Sci 20 (2019). https://doi.org/10.3390/ijms20225522
- 486 3 Milman, A. et al. Profile of patients with Brugada syndrome presenting with their first
- documented arrhythmic event: Data from the Survey on Arrhythmic Events in
- BRUgada Syndrome (SABRUS). Heart Rhythm 15, 716-724 (2018).
- https://doi.org/10.1016/j.hrthm.2018.01.014
- 490 4 Barc, J. et al. Genome-wide association analyses identify new Brugada syndrome risk
- loci and highlight a new mechanism of sodium channel regulation in disease
- susceptibility. Nat Genet 54, 232-239 (2022).
- https://doi.org/10.1038/s41588-021-01007-6
- 494 5 Priori, S. G. et al. Executive summary: HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary 496 arrhythmia syndromes. *Europace* 15, 1389-1406 (2013).
- https://doi.org/10.1093/europace/eut272
- 498 6 Priori, S. G. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: **Association for European Paediatric and Congenital Cardiology (AEPC)**. *Eur Heart J*
- 36, 2793-2867 (2015). https://doi.org/10.1093/eurheartj/ehv316

- 504 7 Al-Khatib, S. M. et al. 2017 AHA/ACC/HRS Guideline for Management of Patients
- 505 With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive
- 506 Summary: A Report of the American College of Cardiology/American Heart
- 507 Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
- 508 Circulation 138, e210-e271 (2018). https://doi.org/10.1161/cir.0000000000000548
- 509 8 Verweij, N. et al. The Genetic Makeup of the Electrocardiogram. Cell Syst 11,
- 510 229-238.e225 (2020). https://doi.org/10.1016/j.cels.2020.08.005
- 511 9 Nauffal, V. et al. Monogenic and Polygenic Contributions to QTc Prolongation in the
- 512 Population. *Circulation* 145, 1524-1533 (2022).
- 513 https://doi.org/10.1161/circulationaha.121.057261
- 514 10 Ferkingstad, E. et al. Large-scale integration of the plasma proteome with genetics
- 515 and disease. *Nat Genet* 53, 1712-1721 (2021).
- 516 https://doi.org/10.1038/s41588-021-00978-w
- 517 11 Sun, B. B. et al. Plasma proteomic associations with genetics and health in the UK
- 518 Biobank. Nature 622, 329-338 (2023). https://doi.org/10.1038/s41586-023-06592-6
- 519 12 Võsa, U. et al. Large-scale cis- and trans-eQTL analyses identify thousands of genetic
- 520 loci and polygenic scores that regulate blood gene expression. Nature Genetics 53,
- 521 1300-1310 (2021). https://doi.org/10.1038/s41588-021-00913-z
- 522 13 Chen, Y. et al. Genomic atlas of the plasma metabolome prioritizes metabolites 523 implicated in human diseases. Nature Genetics 55, 44-53 (2023).
- 524 https://doi.org/10.1038/s41588-022-01270-1
- 525 14 Willer, C. J. et al. Discovery and refinement of loci associated with lipid levels. Nat

526 Genet 45, 1274-1283 (2013). https://doi.org/10.1038/ng.2797

- 527 15 Barton, A. R., Sherman, M. A., Mukamel, R. E. & Loh, P.-R. Whole-exome imputation
- 528 within UK Biobank powers rare coding variant association and fine-mapping analyses.
- 529 Nature Genetics 53, 1260-1269 (2021). https://doi.org/10.1038/s41588-021-00892-1
- 530 16 Evangelou, E. et al. Genetic analysis of over 1 million people identifies 535 new loci
- 531 associated with blood pressure traits. Nat Genet 50, 1412-1425 (2018).
- 532 https://doi.org/10.1038/s41588-018-0205-x
- 533 17 Chen, J. et al. The trans-ancestral genomic architecture of glycemic traits. Nat Genet
- 534 53, 840-860 (2021). https://doi.org/10.1038/s41588-021-00852-9
- 535 18 Soranzo, N. et al. Common variants at 10 genomic loci influence hemoglobin $A_1(C)$
- 536 levels via glycemic and nonglycemic pathways. *Diabetes* 59, 3229-3239 (2010).
- 537 https://doi.org/10.2337/db10-0502
- 538 19 Yengo, L. *et al.* Meta-analysis of genome-wide association studies for height and body
- 539 mass index in ∼700000 individuals of European ancestry. Hum Mol Genet 27,
- 540 3641-3649 (2018). https://doi.org/10.1093/hmg/ddy271
- 541 20 Malik, R. et al. Multiancestry genome-wide association study of 520,000 subjects
- 542 identifies 32 loci associated with stroke and stroke subtypes. Nat Genet 50, 524-537
- 543 (2018). https://doi.org/10.1038/s41588-018-0058-3
- 544 21 Nikpay, M. et al. A comprehensive 1,000 Genomes-based genome-wide association
- 545 meta-analysis of coronary artery disease. Nat Genet 47, 1121-1130 (2015).
- 546 https://doi.org/10.1038/ng.3396
- 547 22 Shah, S. et al. Genome-wide association and Mendelian randomisation analysis

- 548 provide insights into the pathogenesis of heart failure. Nat Commun 11, 163 (2020).
- 549 https://doi.org/10.1038/s41467-019-13690-5
- 550 23 Kurki, M. I. et al. FinnGen provides genetic insights from a well-phenotyped isolated
- 551 population. Nature 613, 508-518 (2023). https://doi.org/10.1038/s41586-022-05473-8
- 552 24 Pattaro, C. et al. Genetic associations at 53 loci highlight cell types and biological
- 553 pathways relevant for kidney function. Nat Commun 7, 10023 (2016).
- 554 https://doi.org/10.1038/ncomms10023
- 555 25 Forgetta, V. et al. Rare Genetic Variants of Large Effect Influence Risk of Type 1
- 556 Diabetes. Diabetes 69, 784-795 (2020). https://doi.org/10.2337/db19-0831
- 557 26 Xue, A. et al. Genome-wide association analyses identify 143 risk variants and 558 putative regulatory mechanisms for type 2 diabetes. Nat Commun 9, 2941 (2018).
- 559 https://doi.org/10.1038/s41467-018-04951-w
- 560 27 Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based
- 561 linkage analyses. Am J Hum Genet 81, 559-575 (2007).
- 562 https://doi.org/10.1086/519795
- 563 28 Hemani, G., Tilling, K. & Davey Smith, G. Orienting the causal relationship between
- 564 imprecisely measured traits using GWAS summary data. PLoS Genet 13, e1007081
- 565 (2017). https://doi.org/10.1371/journal.pgen.1007081
- 566 29 Skrivankova, V. W. et al. Strengthening the Reporting of Observational Studies in
- 567 **Epidemiology Using Mendelian Randomization: The STROBE-MR Statement**. Jama
- 568 326, 1614-1621 (2021). https://doi.org/10.1001/jama.2021.18236
- 569 30 Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic

- 570 association studies using summary statistics. PLoS Genet 10, e1004383 (2014).
- 571 https://doi.org/10.1371/journal.pgen.1004383
- 572 31 Tofighi, D. & MacKinnon, D. P. RMediation: An R package for mediation analysis
- 573 confidence intervals. Behavior Research Methods 43, 692-700 (2011).
- 574 https://doi.org/10.3758/s13428-011-0076-x
- 575 32 Du, L. et al. Dockey: a modern integrated tool for large-scale molecular docking and
- 576 virtual screening. Brief Bioinform 24 (2023). https://doi.org/10.1093/bib/bbad047
- 577 33 Zhang, Q. et al. Increase in CO(2) levels by upregulating late sodium current is
- 578 proarrhythmic in the heart. *Heart Rhythm* 16, 1098-1106 (2019).
- 579 https://doi.org/10.1016/j.hrthm.2019.01.029
- 580 34 Tomek, J., Nieves-Cintron, M., Navedo, M. F., Ko, C. Y. & Bers, D. M. SparkMaster 2:
- 581 A New Software for Automatic Analysis of Calcium Spark Data. Circ Res 133, 450-462
- 582 (2023). https://doi.org/10.1161/circresaha.123.322847
- 583 35 Rimmerman, N. et al. N-palmitoyl glycine, a novel endogenous lipid that acts as a 584 modulator of calcium influx and nitric oxide production in sensory neurons. *Mol*
- 585 Pharmacol 74, 213-224 (2008). https://doi.org/10.1124/mol.108.045997
- 586 36 Bradshaw, H. B., Raboune, S. & Hollis, J. L. Opportunistic activation of TRP receptors
- 587 by endogenous lipids: exploiting lipidomics to understand TRP receptor cellular
- 588 communication. Life Sci 92, 404-409 (2013). https://doi.org/10.1016/j.lfs.2012.11.008
- 589 37 Szentandrássy, N. et al. Effects of rosiglitazone on the configuration of action
- 590 potentials and ion currents in canine ventricular cells. Br J Pharmacol 163, 499-509
- 591 (2011). https://doi.org/10.1111/j.1476-5381.2011.01215.x

- 592 38 Pieroni, M. et al. Electroanatomic and Pathologic Right Ventricular Outflow Tract
- 593 Abnormalities in Patients With Brugada Syndrome. Journal of the American College of
- *Cardiology* **72**, 2747-2757 (2018).
- https://doi.org/https://doi.org/10.1016/j.jacc.2018.09.037
- 596 39 Bonny, A. et al. C-reactive protein levels in the brugada syndrome. Cardiol Res Pract
- 2011, 341521 (2011). https://doi.org/10.4061/2011/341521
- 40 Li, A., Tung, R., Shivkumar, K. & Bradfield, J. S. Brugada syndrome-Malignant **phenotype associated with acute cardiac inflammation?** HeartRhythm Case Rep 3,
- 384-388 (2017). https://doi.org/10.1016/j.hrcr.2017.04.011
- 41 Gijsbers, K. et al. GCP-2/CXCL6 synergizes with other endothelial cell-derived chemokines in neutrophil mobilization and is associated with angiogenesis in
- gastrointestinal tumors. Exp Cell Res 303, 331-342 (2005).
- https://doi.org/10.1016/j.yexcr.2004.09.027
- 605 42 Torán, J. L. et al. CXCL6 is an important paracrine factor in the pro-angiogenic human 606 cardiac progenitor-like cell secretome. Sci Rep 7, 12490 (2017). https://doi.org/10.1038/s41598-017-11976-6
- 608 43 Bahudhanapati, H. et al. Increased expression of CXCL6 in secretory cells drives fibroblast collagen synthesis and is associated with increased mortality in idiopathic 610 pulmonary fibrosis. *Eur Respir J* 63 (2024). https://doi.org/10.1183/13993003.00088-2023
- 44 Shandelya, S. M., Kuppusamy, P., Herskowitz, A., Weisfeldt, M. L. & Zweier, J. L. Soluble complement receptor type 1 inhibits the complement pathway and prevents

- contractile failure in the postischemic heart. Evidence that complement activation is
- 615 required for neutrophil-mediated reperfusion injury. *Circulation* 88, 2812-2826 (1993).
- https://doi.org/10.1161/01.cir.88.6.2812
- 45 Lazar, H. L. et al. Beneficial Effects of Complement Inhibition With Soluble
- Complement Receptor 1 (TP10) During Cardiac Surgery. Circulation 116, I-83-I-88

(2007). https://doi.org/doi:10.1161/CIRCULATIONAHA.106.677914

- 46 Milman, A. et al. Gender differences in patients with Brugada syndrome and
- **arrhythmic events: Data from a survey on arrhythmic events in 678 patients**. *Heart*
- Rhythm 15, 1457-1465 (2018). https://doi.org/10.1016/j.hrthm.2018.06.019
- 47 Li, Q., Wang, P., Ye, K. & Cai, H. Central role of SIAH inhibition in DCC-dependent cardioprotection provoked by netrin-1/NO. Proc Natl Acad Sci U S A 112, 899-904
- (2015). https://doi.org/10.1073/pnas.1420695112
- 48 Ezzili, C., Otrubova, K. & Boger, D. L. Fatty acid amide signaling molecules. Bioorg
- Med Chem Lett 20, 5959-5968 (2010). https://doi.org/10.1016/j.bmcl.2010.08.048
- 628 49 Riccio, A. et al. mRNA distribution analysis of human TRPC family in CNS and
- 629 peripheral tissues. *Brain Res Mol Brain Res* 109, 95-104 (2002).
- https://doi.org/10.1016/s0169-328x(02)00527-2
- 631 50 Bröker-Lai, J. et al. Heteromeric channels formed by TRPC1, TRPC4 and TRPC5
- 632 define hippocampal synaptic transmission and working memory. *Embo i* 36,
- 2770-2789 (2017). https://doi.org/10.15252/embj.201696369
- 51 Du, S. L., Jia, Z. Q., Zhong, J. C. & Wang, L. F. TRPC5 in cardiovascular diseases.
- Rev Cardiovasc Med 22, 127-135 (2021). https://doi.org/10.31083/j.rcm.2021.01.212

 52 Liu, T., Zhao, H., Li, J., Korantzopoulos, P. & Li, G. Rosiglitazone attenuates atrial structural remodeling and atrial fibrillation promotion in alloxan-induced diabetic 638 rabbits. *Cardiovasc Ther* 32, 178-183 (2014). https://doi.org/10.1111/1755-5922.12079 640 53 Clapham, D. E. TRP channels as cellular sensors. Nature 426, 517-524 (2003). https://doi.org/10.1038/nature02196 642 54 Juang, J.-M. J. et al. Validation and Disease Risk Assessment of Previously Reported 643 Genome-Wide Genetic Variants Associated With Brugada Syndrome. *Circulation:* Genomic and Precision Medicine 13, e002797 (2020). https://doi.org/doi:10.1161/CIRCGEN.119.002797 55 Van Hemelrijck, M., Shanmugalingam, T., Bosco, C., Wulaningsih, W. & Rohrmann, S. The association between circulating IGF1, IGFBP3, and calcium: results from 648 NHANES III. *Endocr Connect* 4, 187-195 (2015). https://doi.org/10.1530/ec-15-0039 649 56 Vutthikraivit, W. et al. Worldwide Prevalence of Brugada Syndrome: A Systematic Review and Meta-Analysis. Acta Cardiol Sin 34, 267-277 (2018). https://doi.org/10.6515/acs.201805_34(3).20180302b

Author contribution

 Conceptualization, H.X.; methodology, H.X., B.L.; software, formal analysis, and investigation, H.X.; electrophysiology experiments, H.X., B.L., and Y.C.; validation, H.X., B.L.; writing – original draft, H.X.; writing – review & editing, B.L., L.Y., A.Z., and L.W.; visualization, H.X.,

B.L.; funding acquisition, L.W.; supervision, L.W.

Data availability

 eQTLs: www.eqtlgen.org; deCode pQTLs: www.decode.com/summarydata/; UKB-PPP pQTLs: ukb-ppp.gwas.eu; MetabolitesQTLs: www.ebi.ac.uk/gwas/studies/GCST90199637; Brugada syndrome: www.ebi.ac.uk/gwas/studies/GCST90086158; ECGwas: http://www.ecgenetics.org; QTc interval: https://personal.broadinstitute.org/ryank/Nauffal_2022_QT_GWAS_SAIGE.zip; RNA-seq generated in this manuscript: GEO database under the code GSE278421.

Code availability

Code for MR can be accessed at github.com/HongxuanXu/Multiomics-brugada-mr.

Abbreviations

- BrS: Brugada syndrome
- ICD: implantable cardioverter-defibrillator
- MR: mendelian randomization
- ECG: electrocardiogram
- GWAS: genome-wide association studies
- 672 OTL: quantitative trait loci
- PBMC: peripheral blood mononuclear cell
- IVW: Inverse variance weighted
- ApoA1: apolipoprotein A1
- ApoB: apolipoprotein B
- HDL-C: high-density lipoprotein cholesterol
- LDL-C: low-density lipoprotein cholesterol

- Lp(a): Lipoprotein A
- SBP: systolic blood pressure
- DBP: diastolic blood pressure
- HbA1c: Hemoglobin A1C
- BMI: body mass index
- AF: atrial fibrillation
- CHD: coronary heart disease
- HF: heart failure
- PalGly: N-palmitoylglycine
- APD: action potential duration
- FDG-PET: fluorodeoxyglucose–positron-emission tomography
- NO: Nitric oxide
- DRG: dorsal root ganglion
- DAD: delayed afterdepolarizations
- SCA: sudden cardiac arrest

695 Table 1. Mendelian randomization analysis and colocalization of circulating proteins and

696 transcripts on Brugada syndorme

697

698

699 Table 2. The mediation effect of PalGly affects BrS

Protein	Total effect		Direct effect Direct effect Mediation			Mediation
		A	В	effect		proportion
	β (95% CI)		β (95% CI) β (95% CI)	β (95% CI)	\mathbf{p}	
IGFBP3		0.20 (0.12 to 0.09 (0.05 to 0.35 (0.18 to 0.03 (0.01 to 2.25e-06				$3.05(0.00)$ to
	0.28	0.12)	0.51)	0.04)		24.91)

700 'Total effect' indicates the effect of the circulating proteins on BrS, 'Direct effect A' indicates the 701 effect of the circulating proteins on PalGly, 'Direct effect B' indicates the effect of PalGly on BrS, 702 'Mediation effect' indicates the effect of the circulating proteins on BrS through PalGly. Total 703 effect, direct effect A and direct effect B were derived by IVW; mediation effect was derived by 704 Delta method.

706 Table 3. Mendelian randomization analysis of PalGly, IGFBP3 CXCL6, CR1, and DCC on

707 cardiometabolic diseases

709 Table 4. Mendelian randomization analysis of PalGly, IGFBP3, CXCL6, and CR1 on

710	cardiometabolic factors

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

711

712

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

715 Figure 1. Flowchart of the MR design

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

 Figure 2. Manhattan plot of significant proteins and transcripts. Red symbols indicate high colocalization support. (A) Proteins from deCode. (B) Proteins from UKB-PPP. (C) Transcripts from eQTLgen.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.10.21.24315897;](https://doi.org/10.1101/2024.10.21.24315897) this version posted October 22, 2024. The copyright holder for this

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

721 Figure 3. Sodium current and calcium spark traits induced by the palmitoylglycine.

722 (A) Left: representative peak sodium current ($Na_v1.5$) before and after the PalGly administration 723 in resting state or half inactivation state. The maximum solubility of palmitoylglycine in 724 extracellular fluid is around 1 μ M. Right: normalized current before and after PalGly (n = 5, 725 paired t-test). (B) Left top: representative image of calcium in primary ventricular cardiomyocytes 726 dyed by Fluo4, AM. Left bottom: representative image (standard deviation transformed) of 727 calcium sparks after 20-second 1 Hz filed stimulations. Right: Delta F/F0 representing the 728 amplitude of calcium sparks is significantly higher after PalGly administration (nControl = 11, 729 nPalGLy = 38 from 5 rabbits, unpaired t-test), each dot represents a mean value of calcium sparks 730 of one line-scanned ventricular cardiomyocyte. PalGly: palmitoylglycine.

perpetuity. preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in medRxiv preprint doi: [https://doi.org/10.1101/2024.10.21.24315897;](https://doi.org/10.1101/2024.10.21.24315897) this version posted October 22, 2024. The copyright holder for this

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Figure 4. PalGly binds to and agonizes the hTRPC5 channel

 (A) molecular docking result for PalGly and class 1 hTRPC5. Chain C of hTRPC5 is in cyan, PalGly is in orange, and hydrogen bonds are in magentas. The binding affinity is -5.9 kcal/mol, 3 hydrogen bonds (Gln503, Trp435, Asp433) are formed between PalGly and Chain C of hTRPC5, and 10 hydrophobic interactions (Chain C: Trp435, Met438, Ala441, Ile484, Ile487, Leu491, Leu514, Leu488; Chain D: Thr603, Thr607) are formed. The normalized agonizing effect of PalGly is presented in (B), ML204 is a selective TRPC4/TRPC5 channel inhibitor (≥ 3 cells from 3 dishes, paired t-test). (C) Normalized stimulation curve of PalGly combing rosiglitazone, a 740 TRPC5 activator $(≥ 5$ cells from 3 dishes). The top two panels are representative recordings of

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

741 hTRPC5 current, outward current is in blue, and inward current is in green.

743 Figure 5. PalGly shortens action potential duration and QT interval

744 (A) APD traits of isolated primary rabbit ventricular cardiomyocytes before and after PalGly 745 administration ($n = 8$ from 3 rabbits, paired t-test), representative recording is on the left. (B) ECG 746 and APD traits of isolated Langendorff-perfused rabbit hearts ($n = 8$, paired t-test), representative 747 ECG recording is on the top left and APD recording on the bottom right. APA: action potential 748 amplitude. APD: action potential duration.

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

Figure 6. PalGly alters the transcriptomic and lipidomic profile of neonatal rat cardiomyocytes

(A) Volcano plot and heatmap of differential lipids. (B) LIPEA lipids enrichment. (C) Significant

differential expressed genes. (D) GO and KEGG enrichment. (E) GSEA analysis, GO categories

are on the left and middle, and KEGG categories are on the right.

Figure. S1 Circulating protein levels affect genetically proxied ECG morphology. Top

cis-pQTLs were selected to represent the expression of the specific proteins

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) .

delta F/F

0

It is made available under a [CC-BY-NC-ND 4.0 International license](http://creativecommons.org/licenses/by-nc-nd/4.0/) . perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2024.10.21.24315897;](https://doi.org/10.1101/2024.10.21.24315897) this version posted October 22, 2024. The copyright holder for this
preprint (which was not certified by peer review) is the author/funder, who has granted

P

-
-
- C FC_Down_Only (103)
- Sig_Down (5)

catalytic activity, acting on DNA ubiquitin−like protein ligase activity RNA polymerase II−specific DNA−binding transcri... catalytic activity, acting on RN_a nucleoside−triphosphatase regulator activity

transcription coregulator

−log10(pvalue)

MF of GO enrichment barplot

cell leading edge

nuclear speck

actin cytoskeleton

Golgi membrane

nuclear envelope

ubiquitin ligase complex

spindle

assembly

0 100 200 300 400 Gene Number

> NOD-like receptor signaling IL−17 signaling pathway Pertussis-Rheumatoid arthritis **Measles Tuberculosis** Influenza A TNF signaling pathway Chagas disease Fc epsilon RI signaling pathway B cell receptor signaling pathway Toll-like receptor signaling pathway Lipid and atherosclerosis

LIPEA Pathway Enrichment

−2.0 −1.5 −1.0 −0.5 0.0

A B

E

